{"schema_version":"1.0","type":"article","title":"The Abivax Story: How a European Biotech Became a 14-Fold Market Myth","url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.md","lang":"en","date":"2026-04-08","publish_at":"2026-04-08T10:30:00+08:00","updated_at":"2026-04-08","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-08）。The Abivax Story: How a European Biotech Became a 14-Fold Market Myth。https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-04-08-abivax-14.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}